Neuroscience

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potentialFS001…

5 months ago

Verantos launches Alzheimer’s Disease Pragmatic Registry to support high-validity real-world evidence generation

Pragmatic registry provides high-quality real-world data on Alzheimer's disease, dementia, and mild cognitive impairment for research PALO ALTO, Calif. , July 10,…

6 months ago

Baszucki Group Launches Metabolic Mind Fresh Start Award to Recognize Individuals Who Have Reclaimed Their Mental Health with Ketogenic Therapy

The Fresh Start Award Program will grant up to five individuals a one-time prize of $10,000 to help them reach…

6 months ago

BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents

Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental healthMALVERN, Pa., July 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc.…

6 months ago

Scanning Electrochemical Microscopy (SECM) Market size is set to grow by USD 55.8 million from 2024-2028, Miniaturization of electronic devices boost the market, Technavio

NEW YORK, July 9, 2024 /PRNewswire/ -- Scanning electrochemical microscopy (SECM) is used for imaging and analyzing chemical processes at…

6 months ago

Cresilon’s Revolutionary Hemostatic Gel Technology Shows Promising Results for Treatment of Penetrating Traumatic Brain Injury in Study Performed with Walter Reed Army Institute of Research

Findings from preclinical study demonstrate potential for a field and prehospital treatment following a penetrating TBI NEW YORK, July 9,…

6 months ago

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team

MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…

6 months ago

AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450

– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the…

6 months ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of…

6 months ago

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

6 months ago